Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Evofem Biosciences, Inc.

Ticker
EVFM
Sector
Industry
Report date
November 14, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent business news highlights Evofem Biosciences' strategic activities including support for a merger with Aditxt and licensing agreements expanding its product reach in the Middle East.

Recent developments:
  • Evofem Biosciences gained support for a merger with Aditxt, indicating potential strategic expansion [N8].
  • The company signed a license agreement with Pharma 1 Drug Store for SOLOSEC in the Middle East, expanding its commercial footprint [N8].
  • Regulatory filings for PHEXX and SOLOSEC in the UAE are underway through Pharma 1, supporting international commercialization efforts [S1].
  • Evofem's revenue increased by 16 percent in Q2, reflecting commercial growth [N8].
  • The company signed a sourcing partnership with Windtree aiming to reduce production costs of PHEXX by 60%, targeting improved margins [N8].
Overview

Evofem Biosciences is a San Diego-based commercial-stage biopharmaceutical company specializing in innovative products addressing unmet needs in women's sexual and reproductive health. Its flagship product, PHEXX, is the first FDA-approved hormone-free, on-demand contraceptive vaginal gel in the U.S., launched in 2020. The company expanded its portfolio by acquiring SOLOSEC in 2024, an FDA-approved single-dose oral antimicrobial for bacterial vaginosis and trichomoniasis. Evofem pursues commercialization in the U.S. and international markets through partnerships and licensing, including agreements in the Middle East and North Africa. The company aims to reduce manufacturing costs substantially starting in 2027 and to leverage its U.S. sales force for business development opportunities. The U.S. contraceptive market is sizable, with significant segments of women seeking non-hormonal options, aligning with Evofem's product positioning.

Executive summary

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company focused on women's sexual and reproductive health, with two FDA-approved products: PHEXX, a hormone-free contraceptive gel, and SOLOSEC, an oral antimicrobial for bacterial vaginosis and trichomoniasis. The company has licensed rights for these products in the Middle East and North Africa and aims to reduce manufacturing costs significantly starting in 2027. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. As of September 30, 2026, Evofem reported $1.49 million in cash and equivalents, $5.96 million in current assets, $84.78 million in current liabilities, a current ratio of 0.07, net income of $1.004 million, and basic EPS of $0.01 [S2].

Scenarios for EVFM

Bull case model:

Evofem's innovative, hormone-free contraceptive gel PHEXX addresses a large underserved market segment of women seeking non-hormonal birth control options, including those affected by GLP-1 medications. The addition of SOLOSEC expands the company's portfolio into treatment of common vaginal infections, potentially increasing revenue streams. Strategic licensing agreements in the Middle East and North Africa open international market opportunities. Planned manufacturing cost reductions could improve margins. The experienced leadership team and commercial infrastructure support execution of growth strategies.

Bear case model:

Evofem faces challenges including a low current liquidity position with a current ratio of 0.07 and cash ratio of 0.02 as of September 30, 2026, indicating potential financial constraints. The company operates in a competitive contraceptive market with established hormonal and non-hormonal options. Regulatory approvals and market adoption outside the U.S. depend on partners and regulatory bodies. Manufacturing cost reduction plans are subject to execution risks. The company's financial performance and ability to diversify revenue streams through business development remain critical to long-term sustainability.

Moat:

Evofem's moat derives from its unique product PHEXX, the only FDA-approved hormone-free, on-demand contraceptive vaginal gel, offering a differentiated mechanism of action by maintaining vaginal pH to reduce sperm motility. This product addresses a significant unmet need among women who avoid hormonal contraceptives due to side effects or medical conditions. The acquisition of SOLOSEC complements the portfolio with an FDA-approved oral antimicrobial for common vaginal infections, leveraging overlapping commercial call points. The company's licensing agreements for international markets and plans to reduce manufacturing costs further support competitive positioning. However, the biopharmaceutical industry faces regulatory, competitive, and market adoption challenges that Evofem must navigate.

Risks overview
Risks summary
Evofem's most significant risk relates to its limited liquidity position, which may impact its ability to execute commercialization and cost reduction strategies effectively.
Risks details:

• Financial Liquidity Risk: As of September 30, 2026, Evofem reported a current ratio of 0.07 and cash ratio of 0.02, indicating limited short-term liquidity which may constrain operational flexibility.
• Regulatory and Market Adoption Risk: The company's products require regulatory approvals and acceptance by healthcare providers and patients. International commercialization depends on partners and regulatory filings, which carry inherent uncertainties.
• Competitive Risk: Evofem operates in a competitive contraceptive market with multiple hormonal and non-hormonal options, which may limit market penetration and pricing power.
• Execution Risk on Cost Reduction: Planned manufacturing cost reductions of 55-60% starting in 2027 depend on successful contract negotiations and operational improvements, which may face delays or challenges.

FINAL FORECAST FOR EVFM

Final take one line
Evofem Biosciences operates with clear product differentiation in women's health, supported by detailed SEC disclosures and recent strategic developments, but faces liquidity and execution risks.
Final take 12 to 24 month view

Business trends: Focus on commercializing hormone-free contraceptive PHEXX and antimicrobial SOLOSEC, expanding international licensing, and targeting cost reductions.
Execution milestones: Regulatory filings in UAE, manufacturing cost reduction initiatives, and potential merger with Aditxt.
Key risks: Limited liquidity, regulatory and market adoption uncertainties, competitive pressures, and execution challenges on cost savings.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Evofem Biosciences is a San Diego-based commercial-stage biopharmaceutical company focused on women's sexual and reproductive health [S1].
  • The company commercializes two FDA-approved products: PHEXX, a hormone-free, on-demand contraceptive vaginal gel launched in the U.S. in September 2020, and SOLOSEC, an oral antimicrobial agent for bacterial vaginosis and trichomoniasis acquired in July 2024 and relaunched in November 2024 [S1].
  • PHEXX is the first and only non-hormonal prescription contraceptive vaginal gel in the U.S., used 0-60 minutes prior to intercourse, designed to maintain vaginal pH and reduce sperm motility [S1].
  • SOLOSEC is FDA-approved for treatment of bacterial vaginosis and trichomoniasis in patients 12 years and older and shares a similar commercial call point with PHEXX [S1].
  • The company licenses commercial rights for PHEXX and SOLOSEC in the Middle East and North Africa to Pharma 1 Drug Store, LLC, with regulatory filings underway in the UAE [S1].
  • Evofem aims to reduce manufacturing costs for PHEXX and SOLOSEC by approximately 55-60% starting in 2027 through new manufacturing contracts [S1].
  • The U.S. contraceptive market was valued at $8.8 billion in 2024, with an estimated 15.9 million women not using hormonal contraceptives or LARCs, representing a key target market for PHEXX [S1].
  • The company highlights a sub-market opportunity among women using GLP-1 medications who may require non-oral contraceptive methods, estimating a $904 million addressable market in the U.S. [S1].
  • Evofem's leadership includes CEO Saundra Pelletier with over 26 years of pharmaceutical industry experience and CFO Ivy Zhang with extensive finance and accounting background [S1].
  • Financial snapshot as of September 30, 2026: cash and equivalents $1.49 million (as of March 31, 2026), current assets $5.96 million, current liabilities $84.78 million, current ratio 0.07, cash ratio 0.02, net income $1.004 million, basic EPS $0.01 [S2].
  • The company reported revenue of $100 million as of October 31, 2023 [S2].
  • Recent news includes Evofem Biosciences gaining support for an Aditxt merger and signing licensing agreements for SOLOSEC in the Middle East [N8, N5].
Sources
Sources - Context summary

Generated 2026-11-14

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-11 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-11-14 | www.nasdaq.com | Soybeans Post Friday Gains Following Export Announcements | https://www.nasdaq.com/articles/soybeans-post-friday-gains-following-export-announcements
  • N2 | 2026-11-14 | www.nasdaq.com | Soybeans Popping Higher on Friday Following Export Announcements | https://www.nasdaq.com/articles/soybeans-popping-higher-friday-following-export-announcements
  • N3 | 2026-11-14 | www.nasdaq.com | Tariffs Pushed Prices Up. Why Retail and Industrial Investors Shouldn't Expect a Quick Reversal | https://www.nasdaq.com/articles/tariffs-pushed-prices-why-retail-and-industrial-investors-shouldnt-expect-quick-reversal
  • N4 | 2026-11-14 | www.nasdaq.com | Arrive AI: 3 Key Takeaways for Long-Term Investors | https://www.nasdaq.com/articles/arrive-ai-3-key-takeaways-long-term-investors
  • N5 | 2026-11-14 | www.nasdaq.com | Novo Nordisk Secures EU Approval For FREHEMGO In Haemophilia A | https://www.nasdaq.com/articles/novo-nordisk-secures-eu-approval-frehemgo-haemophilia
  • N6 | 2026-11-14 | www.nasdaq.com | COSCIENS Biopharma Inc. Q3 Loss Widens | https://www.nasdaq.com/articles/cosciens-biopharma-inc-q3-loss-widens
  • N7 | 2026-11-14 | www.nasdaq.com | Alphamin Resources Corp. Profit Climbs In Q3 | https://www.nasdaq.com/articles/alphamin-resources-corp-profit-climbs-q3
  • N8 | 2026-03-12 | www.nasdaq.com | Evofem Biosciences Gains Support for Aditxt Merger | https://www.nasdaq.com/articles/evofem-biosciences-gains-support-aditxt-merger
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine